Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Tipranavir bulk supplier for pharma manufacturers

Tipranavir 250 mg, 100 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Capsules / Oral Solution

Available Strengths: 250 mg, 100 mg/mL

Reference Brands: Aptivus (USA/EU)

Category: Anti Viral

Tipranavir is an antiretroviral medication belonging to the protease inhibitor class. It is used in combination with ritonavir and other antiretroviral agents to treat HIV-1 infection in patients who have developed resistance to other HIV drugs. Tipranavir works by blocking the HIV protease enzyme, which prevents the virus from multiplying and lowers the amount of HIV in the blood.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Tipranavir — third party manufacturing & bulk supply

Tipranavir 250 mg, 100 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Tipranavir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Tipranavir →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Tipranavir is used in combination with ritonavir and other antiretroviral medicines for the treatment of HIV-1 infection in patients who have experienced resistance to multiple protease inhibitors. It helps reduce viral load by inhibiting the HIV protease enzyme, preventing the virus from maturing and multiplying.

Tipranavir is a synthetic non-peptidic protease inhibitor. Its chemical structure is designed to bind to the active site of HIV-1 protease, blocking the enzyme’s function and preventing the formation of infectious viral particles.

The most recognized trade name for Tipranavir is Aptivus.

Aptivus is manufactured by Boehringer Ingelheim.

The generic name of the product is tipranavir.

The commonly known brand name is Aptivus.

Tipranavir (Aptivus) is manufactured by Boehringer Ingelheim in its approved global production facilities. Distribution varies by region based on regulatory approvals.

Related Products

Cobicistat

Strength:
150 mg

Form: Tablets

Reference Brands: Tybost (USA/EU)

View Details
Brincidofovir

Strength:
100 mg, 10 mg/ml

Form: Tablets / Oral suspension

Reference Brands: Tembexa (USA/EU)

View Details
Lenacapavir

Strength:
300 mg, 463.5 mg/1.5 mL

Form: Tablet / Injection

Reference Brands: Yeztugo (USA), Sunlenca (USA)

View Details
Fostemsavir

Strength:
600 mg

Form: Tablets

Reference Brands: Rukobia (USA)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.